BLUEBIRD BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Events.

On June 11, 2021, bluebird bio, Inc. ("bluebird") issued a press release announcing updated clinical data being presented at the Virtual Edition of the 26th Congress of the European Hematology Association from several studies of betibeglogene autotemcel (beti-cel) gene therapy (licensed as ZYNTEGLO™ in the European Union and the United Kingdom) in adult, adolescent and pediatric patients with transfusion-dependent ?-thalassemia (TDT).

The full text of bluebird's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

    Exhibit
      No.                                             Description
     99.1               Press release issued by bluebird bio, Inc. on June 11, 2021.
      104             Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses